2013/4 GaBI Journal Table of Contents


Editor’s Letter

GaBI Journal publishes four issues in 2013


Suggested evaluation of biological drugs role for WHO – Editor’s response

Do low- to middle-income countries need a biosimilar approval pathway based on a full comparability exercise?

Letters to the Editor

Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation

Critical immunogenicity differences will be obscured by a common INN for biosimilars

WHO leadership in public safety on biosimilars to be commended

Biosimilars naming and prescribing policy in Australia


Maximizing quality in the manufacture of biologicals

Original Research

Establishment of reference standards in biosimilar studies

Review Article

Understanding the components of pharmaceutical expenditure—overview of pharmaceutical policies influencing expenditure across European countries

Immunogenicity of biosimilar monoclonal antibodies


Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C

Meeting Report

The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?


Biosimilar development and regulation in Japan



Source URL: https://gabi-journal.net/20134-gabi-journal-table-of-contents.html

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048